The continued use of GLP-1 weight loss drugs could cut mortality rates by up to 6.4% by 2045, according to new research spearheaded by Swiss Re. Titled "The future of metabolic health and weight loss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback